Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Oxford
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is willing and able to give informed consent for participation in the study.
Male or Female, aged 18 years or above.
Fulfil American College of Rheumatology/European League Against Rheumatism criteria (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria or fulfil Classification Criteria for Psoriatic Arthritis 2006 (CASPAR).
Participant has been selected for intra-articular corticosteroid injection as part of their routine clinical care.
Selected joint for biopsy must be minimum Grade 2 synovial thickening for large joint (knee) and medium joint (wrist), or minimum Grade 3 synovial thickening for small joint (metacarpophalangeal).
You may not be if
Current enrolment in any other clinical study involving an investigational study treatment.
Intramuscular, intravenous or intra-articular administration of corticosteroid within 4 weeks prior to baseline visit.
Oral corticosteroid \> 10 mg/day prednisolone or equivalent within 4 weeks prior to baseline visit.
Oral corticosteroid dose not stable for at least 4 weeks prior to baseline visit.
Oral non-steroidal anti-inflammatory drugs (including aspirin \> 75 mg/ day and selective-cyclooxygenase inhibitors) dose not stable for at least 4 weeks prior to baseline visit.
Disease modifying anti-rheumatic drugs (DMARDs) dose not stable for at least 4 weeks prior to baseline visit.
History of septic arthritis.
Participants on warfarin, heparin, low molecular weight heparin, direct oral anticoagulants. Oral anti-platelet agents are permitted.
History of haemophilia.
Clareo Health | Prospective Longitudinal Effects of Intra-articular Corticosteroid Injection on Synovial Fluid Oxygen
